| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Journal of Virology, June 2008, p. 5664-5668, Vol. 82, No. 11
0022-538X/08/$08.00+0 doi:10.1128/JVI.00456-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

National Emerging Infectious Diseases Laboratories Institute,1 Department of Microbiology,2 Department of Medicine, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts,3 Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland,4 Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland,5 Department of Immunology,6 Medical Microbiology, University of Manitoba, 730 William Avenue, Winnipeg, Manitoba, Canada,7 Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada8
Received 2 March 2008/ Accepted 21 March 2008
Recombinant vesicular stomatitis virus (VSV) vectors expressing homologous filoviral glycoproteins can completely protect rhesus monkeys against Marburg virus when administered after exposure and can partially protect macaques after challenge with Zaire ebolavirus. Here, we administered a VSV vector expressing the Sudan ebolavirus (SEBOV) glycoprotein to four rhesus macaques shortly after exposure to SEBOV. All four animals survived SEBOV challenge, while a control animal that received a nonspecific vector developed fulminant SEBOV hemorrhagic fever and succumbed. This is the first demonstration of complete postexposure protection against an Ebola virus in nonhuman primates and provides further evidence that postexposure vaccination may have utility in treating exposures to filoviruses.
Published ahead of print on 2 April 2008.
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|